A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Principal Investigator
Photograph of Steven Schuster

Steven Schuster

Study ID

Protocol Number: 23-1949

More information available at ClinicalTrials.gov: NCT06152575

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers